Healthcare Analysts discuss expanding CorMedix (CRMD) Therapeutics’ Rezzayo for Prophylactic Use on an Analyst/Industry conference call to be held on April 30.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- CorMedix price target raised to $14 from $13 at RBC Capital
- Buy Rating Reiterated on REZZAYO Trial Strength and Safety Profile; $13 Price Target Maintained
- CorMedix Reports Positive Phase III REZZAYO Prophylaxis Results
- CorMedix announces ReSPECT clinical trial met primary endpoint
- 3 ‘Strong Buy’ Low P/E Stocks with Over 40% Upside